The Tumor Suppressive Role of PATZ1 in Thyroid Cancer: A Matter of Epithelial-Mesenchymal Transition

Monica Fedele1, Laura Cerchia1 and Gennaro Chiappetta2

1Institute of Experimental Endocrinology and Oncology (IEOS), National Research Council (CNR), via S. Pansini, 8031 Naples, Italy
2Department of Experimental Oncology, Functional Genomic Unit, National Cancer Institute "Fondazione Giovanni Pascale", IRCCS, via M. Semmola, 8031 Naples, Italy

*Corresponding author: Monica Fedele, Institute of Experimental Endocrinology and Oncology (IEOS), National Research Council (CNR), via S. Pansini 5, 8031 Naples, Italy, Tel: 39-081-5455751; E-mail: mfedele@unina.it

Received date: February 09, 2016; Accepted date: March 31, 2016; Published date: April 07, 2016

Copyright: © 2016 Fedele M. et al., This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

PATZ1 is a chromatin-regulating factor with emerging roles in stemness and cancer. It has been suggested to play a dual oncogene/tumor suppressor role depending on the cellular context, but its function in human tumor biology is still far to be completely elucidated. We have recently identified its tumor suppressive role in thyroid carcinogenesis, possibly through the association between PATZ1 and p53 to oppose epithelial-mesenchymal transition and cell migration. These are major processes in tumor progression, local invasion, metastasis, and therapeutic resistance and play a recognized role in the development of thyroid cancer, particularly anaplastic thyroid carcinoma, but many questions about how they are orchestrated remain open. Elucidation of the mechanisms regulating epithelial-mesenchymal transition and cell migration can suggest new candidates for antimetastatic drug development that could lead to more effective therapies for highly aggressive and lethal thyroid cancers.

Keywords: Epithelial- Mesenchymal transition; Thyroid cancer; PATZ1

Introduction

Epithelial-mesenchymal transition (EMT) is a major mechanism in embryosgenesis, and recent evidence suggests a crucial role in tumor’s invasive and metastatic potential, as well as in therapeutic resistance [1,2]. It consists of a transdifferentiation process by which a fully differentiated epithelial cell acquires mesenchymal traits, and therefore, mesenchymal abilities such as motility and invasiveness [3].

A number of transcription factors are master regulators of key events in the EMT both in development and cancer. These factors, which include the Slug/Snail and Twist families, downregulate molecules involved in stabilizing cell-cell junctions (such as E-cadherin) and upregulate components of the migratory machinery in order to allow the tumor to become invasive [4]. In addition, the tumor suppressor p53 protein maintains a transcriptional program to oppose EMT and cell migration to prevent metastasis [5]. Chromatin repressive complexes add a further complexity level of control, which rather than directly decide the transcription programs, modulate the threshold for transcriptional activation or repression [6].

Recent studies in thyroid tumors, showing EMT, with decreased expression of E-cadherin and β-catenin and up-regulation of Twist, Snail and Slug particularly in anaplastic thyroid carcinoma (ATC) specimens and cell lines [7-9], support the role of EMT in the development of ATC.

The POZ-AT hook-Zinc finger (PATZ1) protein is a transcriptional regulatory factor that can either activate or downregulate gene expression depending on the cellular context [10]. It has been recently indicated as a “stemness factor” [11] and shown to play a critical role in reprogramming somatic cells into pluripotent stem cells [12]. PATZ1 expression is regulated by DNA damage [13] and appears deregulated in different human cancers, suggesting a cancer-related role [14-17], which appears oncogenic or anti-oncogenic depending on the tumor type and likely on the presence/absence of a wild-type p53 protein with which it interacts [10,13]. Consistently, silencing of PATZ1 expression in a p53-null osteosarcoma cell line enhanced its sensitivity to the pro-apoptotic chemotherapeutic agent 5-fluorouracil (5FU), while Patz1-/- mouse embryonic fibroblasts show a decreased number of apoptotic cells, either spontaneous or induced by 5FU treatment, compared with wild-type controls [10]. However, in a colon cancer cell line, even in the presence of a wild-type p53, PATZ1 has been shown to inhibit p53 function [13], supporting the concept that PATZ1 may have opposite roles on p53 in different tumors. In this context, our recent studies show that PATZ1 acts as a tumor suppressor in thyroid cancer via targeting p53-dependent genes involved in EMT and cell migration [17]. Indeed, in a wide panel of thyroid cancer tissues, including well differentiated (WDTC), poorly differentiated (PDTC) thyroid carcinomas and ATC, we showed that its expression is downregulated and the protein delocalized from the nucleus to the cytoplasm in association with the acquisition of a less differentiated phenotype. Then, by re-expressing PATZ1 in undifferentiated thyroid cancer cell lines, we showed it inhibits cellular migration in vitro and promotes Mesenchymal-Epithelial transition (MET) in vivo, supporting a role for PATZ1 in opposing EMT in thyroid carcinogenesis. Importantly, tumors grafted from PATZ1-/- mice were heterogeneous with some patches showing epithelial features (follicular-like structures and E-cadherin expression) and PATZ1 expression, while most of the remaining tissue was characterized by a mesenchymal phenotype and EMT with some patches showing epithelial features (follicular-like structures and E-cadherin expression) and PATZ1 expression, while most of the remaining tissue was characterized by a mesenchymal phenotype and absent expression of PATZ1. Therefore, it is likely that PATZ1 is negatively selected in vivo as a way to allow an EMT phenotype. Consistent with the ability of PATZ1 to interact with p53 and regulate transcription of p53 target genes [10,13], we next showed that in PATZ1-expressing cells the EMT and cell migration gene program,
activated by EGF and negatively regulated by p53, was deregulated. In more details, PATZ1 binds the promoter regions of three genes, EpCam, RhoE and Caldesmon, involved in EMT, cellular migration and invasion, respectively, modulating their transcriptional changes associated with EGF stimulation (Figure 1). According to the functional role of these three genes, the resulting biological effect is a potentiation of the transcriptional program opposing EMT, migration and invasiveness in cells carrying a wild-type p53, and only a partial effect in cells carrying a mutant p53.

Notably, blocking EMT is not yet been used in clinical practice [24] and this may be consequence of the still debated implication of EMT in the metastatic process. This is essentially due to the difficult of discriminating in vivo the mesenchymal tumor cells from neighboring stromal cells, and also because metastatic lesions are mostly epithelial. Even if the latter may be due to the hypothesized MET reverse process, it is unproven that disseminated mesenchymal tumor cells can complete the metastatic cascade producing secondary lesions. Nevertheless, emerging evidence coming from in vitro studies and clinical prognostic data clearly support the contribution of EMT to chemoresistance in various different cancers. Moreover, by using multiple transgenic mouse models of breast cancers, it has been recently shown that while EMT is not required for metastasis formation, it strongly contributes to chemoresistance thus suggesting that specifically targeting EMT tumor cells will be synergistic with conventional chemotherapy [25]. In this context, the close relationship between EMT and ATC may suggest more effective therapies based on reversing this plastic process in order to combat chemoresistance.

Based on our observations, it would be helpful to acquire insights on the cellular mechanisms regulating PATZ1 expression, to find a way to re-express it in cancer cells and possibly block EMT. We recently found that PATZ1 is a ras oncogene-downregulated gene in thyroid carcinogenesis, crucial for the RAS-induced transformed phenotype, including enhanced cell proliferation and capacity to migrate (Vitiello et al. manuscript submitted). A direct regulator of PATZ1 expression in RAS-transformed thyroid cells may be the miR-29b, which is specifically up-regulated upon ras oncogene induction, and specifically targets PATZ1. However, the RAS-miR-29b-PATZ1 axis seems to be active only early upon ras oncogene activation. Then, other late regulatory events, that still need to be elucidated, may occur to keep PATZ1 downregulated. Indeed, it is known that downstream of ras oncogene activation there are different gene regulatory mechanisms, some of which occur early and are often reversible (i.e. miR-21 upregulation), while others, such as DNA methylation and histone acetylation, represent more stable modifications [26]. Further experiments, using demethylation reagents and/or deacetylation inhibitors, will clarify this issue eventually providing the way to re-express PATZ1 in thyroid cancer cells.

Conclusion

Despite the EMT is considered a critical process for the development of metastases and the acquisition of chemoresistance, blocking EMT is not yet been used in clinical practice and only preclinical studies have been so far carried out. In our opinion, these studies should be pursuit, especially as possible therapeutic approach for the ATC, the more aggressive and less therapy-responsive thyroid cancer. In this context, a valuable target may be PATZ1, whose re-expression in ATC cells has been shown to revert EMT tumors grafted in animal models [17].

References

1. Yang J, Weinberg RA (2008) Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Biol 321: 64-76.

---

Citation: Fedele M, Cerchia L, Chiappetta G (2016) The Tumor Suppressive Role of PATZ1 in Thyroid Cancer: A Matter of Epithelial-Mesenchymal Transition. Chemo Open Access 5: 198. doi:10.4172/2167-7700.1000198
2. Thiery JP, Acloque H, Huang RY, Nieto MA (2009) Epithelial-mesenchymal transitions in development and disease. Cell 139: 871-90.

3. Krasnapolski MA, Todaro LB, de Kier Joffé EB (2011) Is the epithelial-to-mesenchymal transition clinically relevant for the cancer patient? Curr Pharm Biotechnol 12: 1891-9.

4. Puisieux A, Brablitz T, Caramel J (2014) Oncogenic roles of EMT-inducing transcription factors. Nat Cell Biol 16: 488-94.

5. Muller PA, Vousden KH, Norman JC (2011) p53 and its mutants in tumor cell migration and invasion. J Cell Biol 192: 209-18.

6. Laugesen A, Helin K (2014) Chromatin repressive complexes in stem cells, development, and cancer. Cell Stem Cell 14: 735-51.

7. Hardy RG, Vicente-Dueñas C, González-Herrero I, Anderson C, Flores T, et al. (2007) Snail family transcription factors are implicated in thyroid carcinogenesis. Am J Pathol 171: 1037-46.

8. Salerno P, García-Rostan G, Piccinin S, Bencivenga TC, Di Maro G, et al. (2011) TWIST1 plays a pleiotropic role in determining the anaplastic thyroid cancer phenotype. J Clin Endocrinol Metab 96: E772-81.

9. Buehler D, Hardin H, Shan W, Montemayor-Garcia C, Rush PS, et al. (2013) Expression of epithelial-mesenchymal transition regulators SNAI2 and TWIST1 in thyroid carcinomas. Mod Pathol 26: 54-61.

10. Valentino T, Palmieri D, Vitello M, Pierantoni GM, Fusco A, et al. (2013) PATZ1 interacts with p53 and regulates expression of p53-target genes enhancing apoptosis or cell survival based on the cellular context. Cell Death Dis 4: e963.

11. Ow JR, Ma H, Jean A, Goh Z, Lee YH, et al. (2014) Patz1 regulates embryonic stem cell identity. Stem Cells Dev 23: 1062-73.

12. Ma H, Ow JR, Tan BC, Goh Z, Feng B, et al. (2014) The dosage of Patz1 modulates reprogramming process. Sci Rep 4: 7519.

13. Keskin N, Deniz E, Eryilmaz J, Un M, Batur T, et al. (2015) ATZ1 Is a DNA Damage-Responsive Transcription Factor That Inhibits p53 Function. Mol Cell Biol 35:1741-53.

14. Trzit R, Mueller BM, Hickey MJ, Lin AH, Gomez GG, et al. (2008) siRNA Down-regulation of the PATZ1 Gene in Human Glioma Cells Increases Their Sensitivity to Apoptotic Stimuli. Cancer Ther 6: 865-76.

15. Fedele M, Franco R, Salvatore G, Paninetti MP, Barbagallo I, et al. (2008) PATZ1 gene has a critical role in the spermatogenesis and testicular tumours. J Pathol 215: 39-47.

16. Yang WL, Ravatn R, Kudoh K, Alabanza L, Chin KV (2010) Interaction of the regulatory subunit of the cAMP-dependent protein kinase with PATZ1 (ZNF278). Biochem Biophys Res Commun 391: 1318-23.

17. Chiappetta G, Valentino T, Vitiello M, Pasquinelli R, Monaco M, et al. (2015) PATZ1 acts as a tumor suppressor in thyroid cancer via targeting p53-dependent genes involved in EMT and cell migration. Oncotarget 6: 5310-23.

18. Pero R, Palmieri D, Angrisano T, Valentino T, Federico A, et al. (2012) POZ-, AT-hook-, and zinc-finger-containing protein (PATZ1) interacts with human oncogene B cell lymphoma 6 (BCL6) and is required for its negative autoregulation. J Biol Chem 287: 18308-17.

19. Cattoretti G, Pasqualucci L, Ballon G, Tam W, Nandula SV, et al. (2005) Deregulated BCL6 expression recapitulates the pathogenesis of human diffuse large B cell lymphomas in mice. Cancer Cell 7: 445-55.

20. Yu JM, Sun W, Hua F, Xie J, Lin H, et al. (2015) BCL6 induces EMT by promoting the ZEB1-mediated transcription repression of E-cadherin in breast cancer cells. Cancer Lett 365: 190-200.

21. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarty AB, et al. (2011) Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 121: 2750-67.

22. Guo Z, Hardin H, Lloyd RV (2014) Cancer stem-like cells and thyroid cancer. Endocr Relat Cancer 21: T285-300.

23. Keutgen XM, Sadowski SM, Kebebew E (2015) Management of anaplastic thyroid cancer. Gland Surg 4: 44-51.

24. Pasquier J, Abu-Kaoud N, Al Thani H, Rafii A (2015) Epithelial to Mesenchymal Transition in a Clinical Perspective. J Oncol 2015: 792182.

25. Fischer KR, Durrans A, Lee S, Sheng J, Li F, et al. (2015) Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature 527: 472-6.

26. Cammarota F, de Vita G, Salvatore M, Laukkanen MO (2015) Ras Oncogene-Mediated Progressive Silencing of Extracellular Superoxide Dismutase in Tumorigenesis. Biomed Res Int 2015: 780409.